Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria [Yahoo! Finance]
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX) [Yahoo! Finance]
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference